Long-term follow-up from the KEYNOTE-522 trial shows improved overall survival with the addition of pembrolizumab compared with placebo.
The KEYNOTE-522 regimen of adding pembrolizumab to chemotherapy and surgery has been widely adopted by clinicians for treatment of stage II/III triple-negative breast cancer based on the previously reported, clinically and statistically significant improvements in pathologic complete response and event-free survival (NEJM JW Oncol Hematol Feb 11 2022 and N Engl J Med 2022 Feb 10; 386:556). Now, after a median follow-up of 75 months, researchers report findings for overall survival, a secondary endpoint.
In the industry-supported, phase 3 KEYNOTE-522 trial, nearly 1200 patients with previously untreated stage II or III triple-negative breast cancer were randomized to receive neoadjuvant pembrolizumab or placebo plus chemotherapy (paclitaxel p…
Reviewing Author
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)